Clinical Trial Update: Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

View source ↗

Summary

This clinical trial investigates plasma molecular profiling to identify resistance mechanisms in ALK-inhibitor resistant non-small cell lung cancer and is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Non-small Cell Lung Cancer, ALK-Positive Lung Cancer | Status: RECRUITING